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Abstract Human uncoupling protein 3 (UCP3) is a mitochon-
drial transmembrane carrier that uncouples oxidative phosphor-
ylation and is a candidate gene for obesity. Expression of native
human UCP3 mutations in yeast showed complete loss (R70W),
significant reduction (R143X), or no effect (V102I and
IVS6+1GsA) on the uncoupling activity of UCP3. It is
concluded that certain mutations in UCP3 alter its functional
impact on membrane potential (v8), possibly conferring
susceptibility to develop metabolic diseases.
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1. Introduction
Uncoupling proteins are mitochondrial transporters that
uncouple mitochondrial respiration from ATP production.
Uncoupling protein 1 (UCP1) is expressed in brown adipose
tissue and is involved in non-shivering and diet-induced ther-
mogenesis [1]. Uncoupling protein 2 (UCP2), on the other
hand, is widely expressed [2] while uncoupling protein 3
(UCP3) is predominantly expressed in skeletal muscle [3,4],
a major tissue contributing to non-shivering thermogenesis
in humans. UCP3 shows high amino acid similarities with
UCP1 (57%) and UCP2 (73%) [5]. Both UCP2 and UCP3
are located on chromosome 11 (11q13) within close proximity
to each other [4]. The UCP1, UCP2, and UCP3 genes consist
of six coding exons, each of which encodes a putative trans-
membrane domain [4,6,7], and UCP1 has been shown to func-
tion as an uncoupler of mitochondrial respiration when ex-
pressed in yeast [8,9]. UCP3 encodes two forms of transcripts :
UCP3L that encompasses all six transmembrane domains and
UCP3S that is missing the sixth coding exon via an alternative
polyadenylation site [4]. UCP3 mRNA levels were shown to
be increased by thyroid hormone, L3-adrenergic agonists, lep-
tin, fasting, fat feeding and cold exposure [5,10^12], under-
scoring its potential role in energy balance.
Mutations and polymorphisms in UCP3 have recently been
identi¢ed in humans [13,14]. A nucleotide substitution that
resulted in a glycine being replaced by a serine at position
84 in a healthy female was reported [13]. In addition, two
polymorphisms, V102I and exon 6 splice donor (IVS6+
1GsA), and a mutation, R143X, were detected in obese
African-Americans [14]. Heterozygotes for the IVS6+1GsA
polymorphism were found to have a 50% reduction in fat
oxidation and a signi¢cant elevation in the non-protein respi-
ratory quotient [14], both of which are metabolic traits that
increase risk of future weight gain. It is noteworthy that the
IVS6+1GsA polymorphism results in the insertion of a pre-
mature stop codon and the resultant protein product is iden-
tical to the short isoform of UCP3. Interestingly, the two
polymorphisms, V102I and IVS6+1GsA, were identi¢ed in
African-Americans and the Mende tribe of Sierra Leone but
not in Caucasians [14]. Recently, we identi¢ed a rare mutation
in UCP3, R70W, in a severely obese and diabetic 15 year old
male of Chinese descent [15]. Alignments showed that the
mutated valine and arginine residues in V102I and R70W
are completely conserved in all UCPs reported to date includ-
ing the plant UCP (PUMP) suggesting that these residues may
play an important functional role.
In this report, the impact of endogenous mutations on mi-
tochondrial uncoupling activity of UCP3 when expressed in
yeast was examined. We report the e¡ect of the four mutant
constructs (V102I, R70W, R143X, and IVS6+1GsA) on
yeast mitochondria. We also discuss the e¡ects of UCP3L
and the four UCP3 mutants on yeast cell growth.
2. Materials and methods
2.1. Construction of the expression vectors
The entire coding region of UCP3 was ampli¢ed from ¢rst strand
cDNA using the expand long template PCR kit (Boehringer-Mann-
heim, Indianapolis, IN, USA) according to the manufacturer’s proto-
col with the following primer pair: UCP3F 5P-tcgctctcgagcctctct-
ccttggacctc-3P and UCP3R 5P-agtatcatcagcggccgcgatgcaccgttttcttccat-
3P. These primers contain the recognition sites for XhoI and NotI,
respectively. The 1017 bp PCR product was cloned into the pYES2
(Invitrogen, Carlsbad, CA, USA) yeast expression vector between the
XhoI and NotI sites. To create the exon 6 splice donor mutation, PCR
was performed using UCP3F and the following reverse primer con-
taining a NotI site: 5P-agtatcatcagcggccgccccttgtagaaggctgtgg-3P. To
create the C208T and G304A mutations, the ExSite PCR-based site-
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directed mutagenesis kit was used according to the manufacturer’s
instructions (Stratagene, La Jolla, CA, USA) with the following
primers: C208TF 5P-tggactgagggtccctgcagcccct-3P and C208TR 5P-ca-
caatggtcaggatggtgcccagc-3P ; G304AF 5P-atcaagcaggtgtacacccccaaa-3P
and G304AR 5P-ggagtcatagaggccgatgcggatg-3P. PCR was performed
with the following primers to create the C427T mutation: C427TF
5P-tgatttcaggccagcatacacctcg-3P and C427TR 5P-gaccttcaccacatctgtgg-
gctgg-3P. All clones were sequenced manually with the Amplicycle
DNA sequencing kit according to the manufacturer’s instructions
(Perkin-Elmer, Foster City, CA, USA) to con¢rm the presence of
the targeted mutations.
2.2. Expression in Saccharomyces cerevisiae
The haploid yeast strain W303-1A (MAT a : ade2-2; trp1-1; can1-
100; leu2-3, 112; his 3-11, 15; ura3-1) was transformed with each of
the cloned mutations as well as with UCP3L and pYES2 vector.
Transformed yeast was selected after 2 days of growth at 30‡C on
SC-ura plates [16]. A representative number of clones were selected
and further plated to obtain isolated colonies that were used in sub-
sequent experiments. Expression of UCP3L and mutant UCP3 under
the control of the GAL1 promoter was induced by growth on 2%
galactose in the absence of glucose. To perform the XTT analysis,
the yeast was grown overnight in SSuc-ura and for 6 h in SGal-ura
before the analysis. For the £ow cytometry analysis, the yeast was
grown overnight at 30‡C in 2 ml of SC-ura. Following the overnight
growth, 0.2 ml was transferred to 2 ml of SSuc-ura and grown for
approximately 15 h. After 15 h, an A600 reading was taken and 1U106
cells were added to 10 ml of SGal-ura and grown for 6 h before the
analysis.
2.3. XTT analysis
After cells were grown as indicated above, 1U106 cells from each
culture were diluted in 200 Wl of SC-ura containing 2% galactose in
eight wells of a 96-well plate (Falcon, Lincoln Park, NJ, USA). The
sodium salt of (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazo-
lium-5-carboxyanilide inner salt) (XTT) was added according to the
manufacturer’s recommendations (Sigma, St. Louis, MO, USA).
Plates were incubated for 4 h at 30‡C. Absorbances at 650 nm and
450 nm were read using the Vmax kinetic microplate reader (Molecular
Devices, Menlo Park, CA, USA). The reference absorbance read at
650 nm was subtracted from the 450 nm reading.
2.4. Flow cytometry
Yeast cells were grown as indicated above, then 2 ml of cells were
transferred to appropriate tubes for analysis in the Epics XL-MCL
£ow cytometer (Beckman-Coulter, Miami, FL, USA). The potential
sensitive dye 3,3P-dihexyloxacarbocyanine iodide (DiOC6 ; Molecular
Probes, Eugene, OR, USA) was added to each set of tubes to a ¢nal
concentration of 1 WM approximately 30 min before analysis. To an
additional set of tubes, the chemical uncoupler carbonyl cyanide m-
chlorophenylhydrazone (CCCP; Sigma, St. Louis, MO, USA) was
added to a ¢nal concentration of 10 WM 10 min before the addition
of DiOC6. Immediately before £ow cytometry, 100 Wl of 0.5 M EDTA
was added to the cells, then the cells were sonicated for approximately
10 s in order to prevent clumping of the cells. The count rate was
automatically set at 50 000 objects. For the expression of results, the
pulse integral of £uorescence on a three-order logarithmic scale was
used.
2.5. Nomenclature
Gene names and mutation/polymorphism symbolisms used in this
manuscript were according to Stylianos E. Antonarakis and the No-
menclature Working Group. Details can be found on the following
URL: http://journals.wiley.com/1059-7794/nomenclature.html.
3. Results
3.1. Expression of UCP3L and mutant UCP3 and e¡ects on
yeast growth
UCP3L was cloned into the pYES2 expression vector. Tar-
geted in vitro mutagenesis was then used to create the four
mutations: R70W, R143X, V102I, and IVS6+1GsA. UCP3L
and mutant inserts in the pYES2 vector were under the con-
trol of the inducible GAL1 promoter; therefore, expression of
UCP3 was repressed by growth on glucose and induced by
growth on galactose. Uniform growth of the yeast was ob-
served when the transformants were plated on complete me-
dium containing glucose as the carbon source (Fig. 1A). How-
ever, after induction of expression of the UCP3 gene by
growth on medium containing galactose as the carbon source,
di¡erent growth patterns were observed among transformants
expressing the various mutants (Fig. 1B). The pYES2 and
R70W transformants were able to grow on minimal medium
containing galactose as the carbon source (Fig. 1B). No
growth of the other transformants was observed under the
same conditions (Fig. 1B). To further study the e¡ect of ex-
pression of the UCP3L and mutant UCP3 proteins, growth
rates in liquid medium containing 2% galactose were moni-
tored by optical density readings at 600 nm (Fig. 2). The OD
is an indirect measure of cell density. Yeast cells transformed
with the pYES2 vector grew logarithmically after 2 h while
R70W transformants began to grow logarithmically after 4 h
of inoculation (Fig. 2). No noticeable increase in growth was
seen in the UCP3L, V102I, R143X and IVS6+1GsA trans-
formants after 10 h of induction (Fig. 2).
Fig. 1. Comparison of yeast growth of transformants expressing hu-
man wild-type and mutant UCP3 constructs. A: Growth of yeast
on medium containing 2% glucose. B: Growth of yeast on medium
containing 2% galactose.
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3.2. E¡ects of UCP3L and mutant UCP3 proteins on
mitochondrial respiratory activity
To examine the e¡ect of the UCP3 mutant proteins on
mitochondrial respiration, the reduction of the sodium salt
of (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-
5-carboxyanilide inner salt) (XTT) by mitochondrial dehydro-
genase enzymes was measured since a direct relationship exists
between XTT-formazen formation and mitochondrial respira-
tory (i.e. electron transport) activity [17]. All of the UCP3
transformants had less formation of XTT-formazen compared
to the pYES2 control transformant indicating less mitochon-
drial activity in these cells (Fig. 3). The R70W transformant,
however, showed more XTT-formazen production than the
other four UCP3 proteins (Fig. 3).
3.3. E¡ects UCP3L and mutant UCP3 proteins on
mitochondrial v8
Coupling between respiration and oxidative phosphoryla-
tion is dependent upon a proton gradient across the mito-
chondrial membrane. To assess e¡ects on this proton gra-
dient, the £uorescence of the mitochondrial v8 sensitive
dye, DiOC6, in the transformed yeast cells was measured us-
ing £ow cytometry. The pYES2 and UCP3L transformants
were used as coupled and uncoupled controls, respectively.
Addition of the chemical uncoupler CCCP resulted in a com-
plete shift of the £uorescence peaks of all transformants to the
left (including pYES2 vector control) indicative of total loss of
v8 in mitochondria (data not shown). The amount of £uo-
rescence observed with the V102I and IVS6+1GsA trans-
formants was similar to the level of £uorescence obtained
with UCP3L suggesting similar capabilities to reduce v8
(Fig. 4A and B). The uncoupling abilities of UCP3L, V102I
and IVS6+1GsA could not be distinguished from the CCCP
control indicating either maximal uncoupling by the UCPs or
less than maximal uncoupling by CCCP (data not shown).
Repetition of the experiment showed similar results. An inter-
mediate level of £uorescence was observed with the R143X
mutant corresponding to intermediate degree of uncoupling
(Fig. 4C). The £uorescence measured in yeast cells trans-
formed with the R70W mutant construct was identical to
that obtained with the pYES2 vector control indicating that
the v8 was not decreased and uncoupling did not occur (Fig.
4D).
4. Discussion
UCP3 appears to participate in thermogenesis and energy
balance [3^5], and signi¢cant linkage and associations have
been reported between markers at the UCP2/UCP3 gene locus
with resting metabolic rate [18] and UCP2 polymorphisms
with metabolic rate during sleep and over 24 h [19]. In the
present study, a novel, non-conservative mutation, R70W,
was found to abolish activity of UCP3 when expressed in
yeast. Another mutation, R143X [14], was found to signi¢-
cantly reduce activity of UCP3 in yeast, whereas two other
mutant constructs (V102I and IVS6+1GsA) [13] showed
equal activity to wild-type UCP3.
Induction of UCP3L, V102I, R143X, and IVS6+1GsA
transformants resulted in cessation of growth compared to
normal growth of yeast expressing the R70W mutant. Similar
observations in growth rate of yeast with UCP3L compared to
pYES2 vector control after induction with galactose have
been reported previously [20]. A common characteristic of
non-dividing cells is a decrease in mitochondrial activity
[20]. Measurement of XTT-formazen production revealed
that each of these cell lines expressing UCP3 genes had a
decrease in mitochondrial respiratory activity (i.e. a reduction
in electron transport) when compared to the pYES2 vector
control. XTT does not measure changes in v8 but rather acts
as an arti¢cial electron acceptor. Thus, the reduction of XTT
by dehydrogenase enzymes of the electron transport chain can
be used to measure mitochondrial activity [17]. The lack of
growth and the decreased mitochondrial activity observed in
yeast containing all UCP3 constructs except for the R70W
mutant suggests an interference with normal yeast mitochon-
drial activity due to the presence of the exogenous, yet active,
UCP3 proteins.
Surprisingly, the R143X mutant protein that contains only
three transmembrane domains still had signi¢cant ability to
Fig. 2. Semi-log plot of yeast growth in liquid medium containing
2% galactose in a 10 h period.
Fig. 3. Measurement of XTT-formazen formation in yeast trans-
formants. Statistical comparisons (ANOVA and Bonferroni multiple
comparison) were performed. The horizontal bars indicate signi¢-
cant di¡erences between pYES2 and the other ¢ve transformants
and between R70W and the remaining four transformants, with P-
values as shown. The data represent means þ S.E.M. of 16 measure-
ments from two independent experiments.
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alter v8 in yeast, albeit half that of UCP3L and the
IVS6+1GsA mutant. This ¢nding suggests that the ¢rst
three transmembrane domains of UCP3 retain a native ability
to alter v8 in yeast mitochondria. It would be of interest to
examine whether the distal transmembrane domains of UCP3
have similar e¡ects on v8 in yeast.
With regard to the IVS6+1GsA polymorphism, it had an
equal ability to alter v8 as UCP3L. It is also noteworthy that
the IVS6+1GsA polymorphism predicts a protein identical
to the short isoform of UCP3 (UCP3S). This suggests that
UCP3S may have similar e¡ects on v8 as the long isoform
of UCP3 (UCP3L) as has been reported previously [21^23].
However, both UCP3L and the IVS6+1GsA mutant had
uncoupling abilities equal to that of CCCP, a chemical un-
coupler. Therefore, it would be di⁄cult to detect small di¡er-
ences in uncoupling between the two UCP3 proteins. An as-
sociation has been reported for the IVS6+1GsA
polymorphism with elevated respiratory quotient and reduced
ability of heterozygotes to oxidize fat [14]. However, in a
recent report by Chung et al. [22], resting metabolic rate,
respiratory quotient and metabolic response to graded exer-
cise were all normal in individuals with the exon 6 splice
variant of UCP3 [22]. The inconsistencies between the two
studies may be explained by the di¡erences in Caucasian ad-
mixture proportions in the two African-American popula-
tions. The estimate of admixture in the African-American
population from Maywood, IL, USA examined by Chung et
al. [22] is 18.8% [24] while the Charleston, S.C. Gullah-speak-
ing African-American population studied by Argyropoulos et
al. [14] is estimated to have Caucasian admixture levels of
6.7% (Dr. Shriver, personal communication). The elevated
respiratory quotient and the reduced ability to oxidize fat
could, therefore, be attributed to the lower Caucasian contri-
bution to the Gullah-speaking African-American population.
Furthermore, the ability of the IVS6+1GsA variant to alter
v8 in yeast does not re£ect all possible functions of UCP3.
Indeed, polarographic measurement of the e¡ect of UCP3 on
state 4 respiration in isolated mitochondria has shown that
UCP3 has true uncoupling activity [21] and micro-calorimetric
measurement of direct heat production of whole yeast cells
showed that UCP3 has intrinsic thermogenic properties [25].
It is, therefore, conceivable that these uncoupling and thermo-
genic properties of UCP3 could be compromised by the
IVS6+1GsA polymorphism in humans and could account
for the apparent lack of correlation between the reported
phenotype in humans [14] and the yeast studies presented
here.
The R70W mutation, on the other hand, had the most
Fig. 4. Flow cytometry analysis of the mitochondrial membrane potential gradient in yeast expressing wild-type and mutant UCP3. The num-
ber of cells (y-axis) relative to logarithmic intensity of £uorescence of the potential sensitive dye DiOC6 (x-axis) is shown. Each panel compares
the £uorescence of a mutant UCP3 protein with wild-type UCP3 and pYES2 vector control. A: V102I; B: IVS6+1GsA; C: R143X; D:
R70W. Consistent results were obtained from three independent £ow cytometry experiments.
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signi¢cant impact on UCP3 by completely abolishing its abil-
ity to alter v8. Moreover, this mutant protein had no delete-
rious e¡ect on yeast growth, unlike the wild-type UCP3 iso-
form, suggesting that this mutation may alter a critical
functional domain in the protein. It is tempting to speculate
that the mutant R70W UCP3 protein loses its capacity to
enter the mitochondrial membrane or that it is inserted into
the mitochondrial membrane but loses its ability to alter v8.
Furthermore, it has been demonstrated that certain arginines
(R83, R182 and R276) are essential for nucleotide interaction
with UCP1 [26]. Based on the putative topology of UCP3
[13,24], the R70W missense mutation is located in the second,
matrix-orientated, extramembranous loop. Using simulation
software [27], substitution of the arginine residue by trypto-
phan at position 70 changed the predicted secondary structure
of UCP3 by elongating a L-sheet at the point of the mutation.
Therefore, the R70W mutation may also result in conforma-
tional changes that could a¡ect functional properties of the
UCP3 protein.
In conclusion, native mutations in UCP3 abolished (R70W)
or reduced (R143X) the ability of the protein to alter v8.
Expression of UCP3 constructs in yeast is useful for studying
relative di¡erences in function. However, the yeast system
may not re£ect UCP3 function as it may exist in mammalian
mitochondria and a primary role for UCP3 in regulating fuel
availability in mammals may not be evident in yeast trans-
formants. Nevertheless, endogenous UCP3 mutations can
clearly alter its ability to change v8 and may potentially
confer susceptibility to develop metabolic disease. Further ex-
periments in mammalian cells and/or animal models may be
required to assess the physiological properties of UCP3 gene
variants in mammalian mitochondria.
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